Synopsis: Fredun Pharmaceuticals Limited reported strong FY26 revenue and profitability growth driven by robust pharmaceutical exports and rising demand across healthcare and nutraceutical products. The company also announced a final dividend of 70 paise per share for shareholders.
Pharmaceutical stock gained attention after reporting strong operational and profitability growth during FY26 along with announcing a final dividend for shareholders. The company continued benefiting from higher demand across pharmaceutical formulations, healthcare products and export-focused operations.
Fredun Pharmaceuticals Limited has a total market capitalization of Rs. 1,289.37 crore, according to data on the BSE. Fredun Pharmaceuticals shares were trading at Rs. 2366 apiece on the National Stock Exchange, down by 0.76 percent; the stock has surged around 0.45 percent over the last five sessions, while it has gone up about 16.02 percent in the 30 days. Over a six-month period, the stock has given a positive return of 26.66 percent, whereas on a year-on-year basis it has surged nearly 220.29 percent, reflecting positive overall performance. The stock’s 52-week high was Rs. 2620 and 52-week low was Rs. 690.
Fredun Pharmaceuticals Limited reported audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company posted revenue from operations of Rs. 210.41 crore in Q4FY26 compared to Rs. 165.44 crore in Q4FY25, reflecting strong growth of around 27.2 percent year-on-year. Quarter over quarter, revenue also improved significantly from Rs. 159.93 crore reported in Q3FY26.
Total income for the quarter stood at Rs. 213.05 crore in Q4FY26 compared to Rs. 167.41 crore in the corresponding quarter last year, reflecting growth of around 27.3 percent year-on-year. The increase was mainly supported by higher pharmaceutical product sales, export demand and improved contribution from healthcare and nutraceutical businesses.
On the profitability front, the company reported net profit of Rs. 10.78 crore in Q4FY26 compared to Rs. 6 crore in Q4FY25, reflecting strong growth of around 79.6 percent year-on-year. Quarter over quarter, profit also improved from Rs. 10.48 crore reported in Q3FY26. Profit before tax stood at Rs. 11.25 crore in Q4FY26 compared to Rs. 7.26 crore in Q4FY25, reflecting growth of around 54.8 percent year-on-year.
One of the major factors supporting profitability during the quarter was strong operational growth and better scale efficiencies despite increase in employee and finance-related expenses. Total expenses increased to Rs. 201.81 crore in Q4FY26 compared to Rs. 160.14 crore in Q4FY25, reflecting an increase of around 26 percent year-on-year due to higher business activity and manufacturing costs.
For the full financial year FY26, Fredun Pharmaceuticals reported revenue from operations of Rs. 633.33 crore compared to Rs. 451.71 crore in FY25, reflecting strong growth of around 40.2 percent year-on-year. Net profit increased sharply to Rs. 32.62 crore in FY26 compared to Rs. 19.74 crore in FY25, registering growth of around 65.2 percent year-on-year.
Profit before tax for FY26 stood at Rs. 46.99 crore compared to Rs. 27.49 crore in FY25, reflecting strong growth of around 71 percent year-on-year. Earnings per share (EPS) for FY26 improved significantly to Rs. 66.81 compared to Rs. 41.79 reported in the previous financial year.
The Board of Directors recommended a final dividend of 70 paise per equity share having face value of Rs. 10 each for FY26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The dividend recommendation reflects management’s confidence in the company’s operational performance and future growth outlook.
Incorporated in 1987, Fredun Pharmaceuticals Limited manufactures and exports pharmaceutical and healthcare products. The company produces pharmaceutical formulations including tablets, syrups, capsules and ointments across multiple therapeutic categories and has also expanded into nutraceuticals, herbal supplements, diagnostic kits and animal healthcare products.
India’s pharmaceutical sector continues benefiting from rising healthcare demand, increasing exports and growing focus on specialty formulations and nutraceutical products. Companies with export-oriented operations and diversified healthcare portfolios are expected to benefit from long-term industry growth trends.
Overall, Fredun Pharmaceuticals reported strong FY26 operational and profitability growth supported by healthy pharmaceutical demand and export growth. Going forward, export expansion, product diversification, operational efficiency and margin management will remain key factors influencing the company’s future performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Fredun Pharmaceuticals Rallies 220% YoY; Q4 FY26 Profit Surges 80% appeared first on Trade Brains.